Compare SKY & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKY | TARS |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.6B |
| IPO Year | 1994 | 2020 |
| Metric | SKY | TARS |
|---|---|---|
| Price | $88.70 | $73.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $101.83 | $98.89 |
| AVG Volume (30 Days) | 558.2K | ★ 706.2K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.02 | ★ 48.21 |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $2,663,639,000.00 | $451,360,000.00 |
| Revenue This Year | $4.80 | $63.49 |
| Revenue Next Year | $7.49 | $24.68 |
| P/E Ratio | $95.33 | ★ N/A |
| Revenue Growth | 7.26 | ★ 146.71 |
| 52 Week Low | $63.87 | $53.89 |
| 52 Week High | $99.17 | $91.53 |
| Indicator | SKY | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 63.73 | 52.49 |
| Support Level | $73.10 | $68.56 |
| Resistance Level | $89.89 | $74.51 |
| Average True Range (ATR) | 2.93 | 3.19 |
| MACD | 1.22 | 0.56 |
| Stochastic Oscillator | 92.14 | 72.22 |
Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several locations across the US. The Company has two reportable segment U.S. Factory-built Housing and Canadian Factory-built Housing. The majority of the revenue is generated from U.S. Factory-built Housing.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.